#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Crigler-Najjar syndrome Chronic inflammatory demyelinating polyradiculoneuropathy HER2 mutant non-small cell lung cancer Thromboangiitis obliterans Pancreatic carcinoma metastatic Sickle cell anaemia Biotinidase deficiency Chronic lymphocytic leukaemia Congenital aplastic anaemia Metastatic gastric cancer Frontotemporal dementia Post transplant lymphoproliferative disorder Anti-HLA antibody test positive Primary immunodeficiency syndrome Dementia with Lewy bodies More trials…

    Learn about Rare Diseases

    Rhabdoid tumour Cystic fibrosis lung – Diagnostics Pemphigoid – Treatment Chondrosarcoma – Treatment Osteosarcoma Stevens-Johnson syndrome – Life with Disease Prader-Willi syndrome – Diagnostics Mucopolysaccharidosis – Basic Information Waldenstrom’s macroglobulinaemia – Diagnostics Primary mediastinal large B-cell lymphoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Menotrophin Aaa802 Specific Nucleic Acid Sna-Veru Midostaurin Poloxamer 407 Technetium (99Mtc) Poractant Alfa Cd19-Car_Lenti_Allo Selinexor Alxn1850 Lna043 GXV813 Landiolol Hydrochloride Atacicept Sodium Chloride Solution 0.9% Olive Oil, Refined Vx-670 Salbutamol Ioflupane (123I) AZD4360 More therapies…

    Learn about Your Condition

    Pancreatic carcinoma stage IV Allergic respiratory disease Thymic carcinoma Leukocyte adhesion deficiency Basal cell naevus syndrome Lymphangioleiomyomatosis Hand dermatitis Lip and/or oral cavity cancer Hydrocephalus Obesity Adenocarcinoma of colon Double hit lymphoma Acarodermatitis Oesophageal carcinoma Juvenile spondyloarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    • Age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Austria Czechia Denmark France Germany Greece +3

  • Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer’s Disease over 72 weeks

    Recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • VHB937
    Czechia France Germany Italy The Netherlands Poland +2

  • Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • VISUGROMAB
    • Sodium Chloride
    • Docetaxel
    Germany Italy Poland Romania Spain

  • Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder

    Recruiting

    3 1 1
    Czechia Germany Greece Ireland Poland

  • Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Gemcitabine Hydrochloride
    • Paclitaxel Albumin-Bound
    • Sacituzumab Tirumotecan
    Belgium Czechia Denmark Finland France Germany +7

  • Study of Atomoxetine to Reduce Freezing of Gait in Patients with Parkinson’s Disease During OFF-State

    Recruiting

    3 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Atomoxetine
    The Netherlands
Previous Page
1 … 161 162 163 164 165 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!